Compare Pfizer Inc (PFE) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs IAC/Interactivecorp — how do they compare? Pfizer Inc trades at $27.78 (market cap $159.59B), while IAC/Interactivecorp trades at $40.94 (market cap $3.02B). The key difference: Pfizer Inc is far larger — about 52.8× IAC/Interactivecorp's market cap, and Pfizer Inc pays a 6.14% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and IAC/Interactivecorp for 79 Days on average.
| PFE | PPLI | |
|---|---|---|
Market Cap | $159.59B | $3.02B |
Volume | 30,937,010 | 932,191 |
Sector | Health | Media |
52-Week High | $29.02 | $47.62 |
52-Week Low | $23.67 | $31.52 |
Typical Hold Time | 158 Days | 79 Days |
Enterprise Value | $211.09B | $3.51B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
PPLI trades at $40.93, down 0.87% on the day, with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility, including a significant Q2 2026 beat. Fundamentals reveal mixed performance with negative 2025 net income but improving 2026 projections, while valuation metrics appear attractive with P/E of 6.87 and P/B of 0.59.
The outlook remains positive due to potential MGM acquisition interest and improving 2026 profitability projections, though risks include inconsistent earnings history and negative cash flow trends. Institutional sentiment is bullish with no sell ratings, supporting near-term upside potential if acquisition talks materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
